--- title: "Pre-market trend | BAYZED HEALTH (2609.HK) Short-term bulls emerge on April 30, is there an undercurrent in the healthcare sector?" type: "News" locale: "en" url: "https://longbridge.com/en/news/284729853.md" description: "At yesterday's close, BAYZED HEALTH had a trading volume of approximately HKD 45.49 million, showing relatively active performance among small and mid-cap medical stocks. The MACD daily line has shown bullish signals above the zero axis, and the short-term moving averages are turning upwards, which is typically interpreted by the market as a confirmation signal of a phase upward trend, indicating that buying power is quietly recovering. Recently, BAYZED HEALTH's performance has gradually emerged from the bottom consolidation range, with moderate volume expansion indicating that funds are positioning at lower levels. On the news front, the Hong Kong stock market's pharmaceutical sector has recently shown a divergence in performance, with Innovent Biologics surging 6.01% yesterday, and 3SBio rising 4.14%, while the innovative drug sub-sector has attracted active capital. Leading CXOs like BeiGene and WuXi Biologics have shown relatively weak performance, with clear rotation characteristics within the sector. As a participant in the healthcare services field, BAYZED HEALTH benefits from the long-term logic of sustained growth in domestic healthcare demand. In April, the PMI service index was 49.6%, slightly below the boom-bust line, but healthcare services, as a necessity, are relatively less affected by economic cycle fluctuations. At the same time, the Federal Reserve's policy tone of maintaining interest rates has somewhat alleviated the pressure of capital outflow, which is beneficial for stabilizing the valuations of small and mid-cap stocks in the Hong Kong market. From a technical perspective, the bullish signals above the zero axis provide directional reference, but the current trading volume level remains moderate. To further confirm the upward trend, sustained volume support is needed. Today, attention should be paid to the overall capital flow in the pharmaceutical sector and whether this stock can maintain active buying interest during the trading session. The divergent performance of the innovative drug and healthcare services sub-sectors will influence the direction of capital allocation" datetime: "2026-05-04T01:00:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284729853.md) - [en](https://longbridge.com/en/news/284729853.md) - [zh-HK](https://longbridge.com/zh-HK/news/284729853.md) --- # Pre-market trend | BAYZED HEALTH (2609.HK) Short-term bulls emerge on April 30, is there an undercurrent in the healthcare sector? Yesterday's closing, BAYZED HEALTH had a trading volume of approximately HKD 45.49 million, showing relatively active performance among small and mid-cap medical stocks. The MACD daily line showed a bullish signal above the zero line, and the short-term moving averages are turning upwards, which is usually interpreted by the market as a confirmation signal of a phase upward trend, indicating that buying power is quietly recovering. Recently, BAYZED HEALTH's performance has gradually emerged from the bottom consolidation range, with a moderate increase in volume indicating that funds are positioning at low levels. On the news front, the Hong Kong stock pharmaceutical sector has recently shown a divergence in performance, with Innovent Biologics surging 6.01% yesterday, and 3SBio rising 4.14%, as the innovative drug sub-sector received active capital support. However, leading CXO companies like BeiGene and WuXi Biologics showed weaker performance, with clear rotation characteristics within the sector. As a participant in the medical services field, BAYZED HEALTH benefits from the long-term logic of sustained growth in domestic medical demand. The PMI service index in April was 49.6%, slightly below the boom-bust line, but medical services, as a necessity, are relatively less affected by economic cycle fluctuations. At the same time, the Federal Reserve's policy tone of maintaining interest rates has somewhat alleviated the pressure of capital outflow, which is beneficial for stabilizing the valuations of small and mid-cap stocks in Hong Kong. From a technical perspective, the bullish signal above the zero line provides directional reference, but the current trading volume level remains moderate. To further confirm the upward trend, sustained volume support is needed. Today, attention should be paid to the overall capital flow in the pharmaceutical sector and whether this stock can maintain active buying during the trading session. The divergent performance of the innovative drug and medical services sub-sectors will influence the direction of capital allocation. The short-term trend is referenced as neutral to slightly bullish, with initial technical improvements, but the liquidity of small and mid-cap medical stocks is limited, and the impact of external risk events may be amplified. If the sector's heat fades or the overall market significantly weakens, the difficulty of maintaining independent strength will increase significantly. _This article only provides technical analysis and market information for reference and does not constitute any investment advice. The market carries uncertainties, and investors should make independent decisions based on their own circumstances._ ### Related Stocks - [02609.HK](https://longbridge.com/en/quote/02609.HK.md) - [159929.CN](https://longbridge.com/en/quote/159929.CN.md) - [516820.CN](https://longbridge.com/en/quote/516820.CN.md) - [513060.CN](https://longbridge.com/en/quote/513060.CN.md) - [159859.CN](https://longbridge.com/en/quote/159859.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [588860.CN](https://longbridge.com/en/quote/588860.CN.md) - [516610.CN](https://longbridge.com/en/quote/516610.CN.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [588250.CN](https://longbridge.com/en/quote/588250.CN.md) - [513700.CN](https://longbridge.com/en/quote/513700.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [159102.CN](https://longbridge.com/en/quote/159102.CN.md) - [560600.CN](https://longbridge.com/en/quote/560600.CN.md) - [01801.HK](https://longbridge.com/en/quote/01801.HK.md) - [01530.HK](https://longbridge.com/en/quote/01530.HK.md) - [688235.CN](https://longbridge.com/en/quote/688235.CN.md) - [06160.HK](https://longbridge.com/en/quote/06160.HK.md) - [ONC.US](https://longbridge.com/en/quote/ONC.US.md) - [02269.HK](https://longbridge.com/en/quote/02269.HK.md) - [688336.CN](https://longbridge.com/en/quote/688336.CN.md) - [BGNE.US](https://longbridge.com/en/quote/BGNE.US.md) - [WXXWY.US](https://longbridge.com/en/quote/WXXWY.US.md) ## Related News & Research - [DOJ Launches Criminal Probe Into Blue State Hospital](https://longbridge.com/en/news/286157785.md) - [Zai Lab Q1 2026 Results Highlight Pipeline Momentum and Upcoming China Launches](https://longbridge.com/en/news/285564515.md) - [01:00 ETNational Kidney Foundation Innovation Fund Invests in Biohope to Advance Personalized Medicine in Kidney Transplantation](https://longbridge.com/en/news/286359416.md) - [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md) - [Manulife Singapore to offer multi-cancer blood test starting May](https://longbridge.com/en/news/286710691.md)